Virogin Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Virogin Biotech's estimated annual revenue is currently $10.2M per year.
- Virogin Biotech's estimated revenue per employee is $155,000
Employee Data
- Virogin Biotech has 66 Employees.
- Virogin Biotech grew their employee count by 5% last year.
Virogin Biotech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Human Resources Director | Reveal Email/Phone |
3 | Director Clinical Projects and Operations | Reveal Email/Phone |
4 | Director Research | Reveal Email/Phone |
5 | Assistant Manager | Reveal Email/Phone |
6 | Assistant Manager | Virus Production | Reveal Email/Phone |
7 | Assistant Manager | Reveal Email/Phone |
8 | Assistant Manager Cell Culture | Reveal Email/Phone |
9 | Clinical Operations Lead | Reveal Email/Phone |
10 | Research Technician | Reveal Email/Phone |
Virogin Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.4M | 22 | 10% | N/A | N/A |
#2 | $10.2M | 66 | 5% | N/A | N/A |
#3 | $13.5M | 87 | 24% | N/A | N/A |
#4 | N/A | 88 | 60% | N/A | N/A |
#5 | $6M | 39 | 26% | N/A | N/A |
#6 | $11.8M | 76 | 41% | N/A | N/A |
#7 | $7.1M | 46 | 59% | N/A | N/A |
#8 | $6.7M | 43 | 139% | N/A | N/A |
What Is Virogin Biotech?
Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance the systemic antitumor immunity in relapsed/refractory cancers. Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies for relapsed/refractory cancers to market.
keywords:N/A
N/A
Total Funding
66
Number of Employees
$10.2M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Richmond
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16M | 66 | 25% | N/A |
#2 | $13.5M | 66 | 5% | N/A |
#3 | $9.5M | 66 | 29% | N/A |
#4 | $21M | 66 | 2% | N/A |
#5 | $7.5M | 66 | 6% | N/A |